MedTrace Logo

Darunavir and Rilpivirine Interactions With Levonorgestrel Implant

NCT03589027 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-03-28

No results posted yet for this study

Summary

This study will evaluate the pharmacokinetic properties of Rilpivirine and Darunavir when used in combination with Levonorgestrel

Conditions

Interventions

DRUG

Levonorgestrel two rod sub-dermal implant

Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally

DRUG

Rilpivirine

Oral ripilvirine 25mg once daily

DRUG

Darunavir+Ritonavir

Oral DRV/r 600/100mg twice daily

Sponsors & Collaborators

  • University of Nebraska

    collaborator OTHER

  • University of Pittsburgh

    collaborator OTHER

  • University of Liverpool

    collaborator OTHER

  • Makerere University

    lead OTHER

Principal Investigators

  • Mohammed Lamorde, PhD · Infectious Diseases Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-07
Primary Completion
2019-06-30
Completion
2020-06-30

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03589027 on ClinicalTrials.gov